LONDON, Dec. 10,2013 /PRNewswire/ --Edison's ADR outlook note, Orphan opportunities, highlights that 2014 could be transformative for GW as its pipeline delivers important clinical milestones. GW's acceleration of orphan programmes in childhood epilepsy (Epidiolex) and primary brain cancer (THC:CBD combination) should generate clinical data and Phase II starts for both indications. In addition, the company's lead programme, Sativex, is approaching key value inflection points including Phase III cancer pain data (Q414) and the US Phase III start in MS spasticity (H214).
Edison's healthcare team forecasts peak sales for Epidiolex in Dravet syndrome (DS) of $288m, THC/CBD (GBM) of $246m and GWP42004 (type 2 diabetes) of $1,025m. It projects Sativex peak sales potential of $814m - MS Spasticity at $278m (US $176m, ex-US $102m) and cancer pain at $536m (US $350m, ex-US $186m).
Edison's revised DCF valuation is $715m, or $48.30 per ADR, following the inclusion of R&D pipeline programmes. Positive data from physician-led studies of Epidiolex (mid-2014 onwards) would see the DCF rise to $818m or $55.30/ADR. Positive Sativex Phase III data in cancer pain (late 2014) would see the DCF rise further to $867m or $58.60/ADR. GW's remaining R&D programmes (epilepsy, ulcerative colitis and schizophrenia) offer pure upside to Edison's valuation.
For the full report see: www.edisoninvestmentresearch.com/research/company/GW-Pharmaceuticals
About Edison Investment Research
This continued ADR coverage on GW Pharmaceuticals is part of a programme of research coverage on pharmaceutical companies exposed to global market opportunities. Edison provides detailed research on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website www.edisongroup.com.
Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do'sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact: | ||
Lala Gregorek | Edison Investment Research | +44 (0)20 3681 2527 |
Robin Davison | Edison Investment Research | +44 (0)20 3077 5737 |
healthcare@edisongroup.com | ||
About GW Pharmaceuticals
GW Pharmaceuticals is a UK specialty pharma company focused on developing cannabinoids as pharmaceuticals. Lead product Sativex is marketed in a number of European countries for multiple sclerosis-associated spasticity.
SOURCE Edison Investment Research
